Ocular Hypertension News and Research

RSS

Danube Pharmaceuticals starts trial of DNB-001 in patients with ocular hypertension

Danube Pharmaceuticals, Inc. has announced the initiation of a multi-center, randomized, double-blind, placebo controlled Phase II study with DNB-001 in 60 patients with ocular hypertension (elevated intraocular pressure).

18 May 2007

Treating glaucoma early significantly reduces economic health burden

Treatments that delay the progression of glaucoma may significantly reduce the economic health burden on people with the disease and on the U.S. health system, according to a new study by researchers at Duke University Eye Center and elsewhere. Their findings appear in the January 9, 2006, issue of Archives of Ophthalmology.

9 Jan 2006

New glaucoma risk calculator

High eye pressure is the leading risk factor for glaucoma, and is the only modifiable one. If glaucoma is untreated, vision loss may continue, leading to blindness in some individuals.

17 Oct 2005

New glaucoma risk assessment principles help physicians decide who needs treatment

A new approach for assessing glaucoma risk factors could be the first step in helping ophthalmologists determine the risk of progression from ocular hypertension to glaucoma and blindness, according to an article published today in the September issue of the American Journal of Ophthalmology.

14 Sep 2004

Latinos living in the United States have high rates of eye disease and visual impairment

Researchers found that Latinos had high rates of diabetic retinopathy, an eye complication of diabetes; and open-angle glaucoma, a disease that damages the optic nerve.

9 Aug 2004

Eye drops may prevent the onset of glaucoma in African Americans

Eye drops that reduce elevated pressure inside the eye can delay or possibly prevent the onset of glaucoma in African Americans at higher risk for developing the disease, researchers have found.

14 Jun 2004